RWMG
KPTI icon

Redwood Wealth Management Group’s Karyopharm Therapeutics KPTI Stock Holding History

Redwood Wealth Management Group’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,269
Closed -$29.5K – 661
2024
Q2 		$29.5K Buy
+2,269
New +$37.6K 0.02% 384
2024
Q1 		– Sell
-1,982
Closed -$25.7K – 130
2023
Q4 		$25.7K Sell
1,982
-200
-9% -$2.69K 0.03% 135
2023
Q3 		$43.9K Hold
2,182
– – 0.05% 133
2023
Q2 		$58.6K Hold
2,182
– – 0.07% 137
2023
Q1 		$127K Sell
2,182
-33
-1% -$1.63K 0.14% 131
2022
Q4 		$113K Buy
+2,215
New +$154K 0.14% 121

Other funds holding KPTI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Redwood Wealth Management Group's KPTI Position: Q3 2024 in Review

Redwood Wealth Management Group sold out of Karyopharm Therapeutics (KPTI) in Q3 2024, closing a stake of 2,269 shares — an estimated $29.5K sold.

Redwood Wealth Management Group first reported a position in KPTI in Q4 2022 and held it in 6 quarters. The position peaked at $127K in Q1 2023. 91 funds tracked by Wall St. Rank hold KPTI as of Q3 2024.

  • Redwood Wealth Management Group reported no remaining Karyopharm Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Redwood Wealth Management Group sold 2,269 Karyopharm Therapeutics shares in Q3 2024, an estimated $29.5K.
  • Redwood Wealth Management Group first reported a position in Karyopharm Therapeutics in Q4 2022 and held it in 6 quarters.
  • Redwood Wealth Management Group's Karyopharm Therapeutics position peaked at $127K in Q1 2023.
  • 91 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2024.

Based on Redwood Wealth Management Group's 13F filing for Q3 2024, filed 13 Nov 2024.